Schedule 13D ownership disclosure

MARKER THERAPEUTICS INC

Common Stock, par value $0.001 per share · CUSIP: 57055L206

Event date: 2025-08-14

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • New Enterprise Associates 16, L.P.Reported CIK 0001694560

    Shares: 1,625,678.00 · Class: 12.6%

  • NEA Partners 16, L.P.Reported CIK 0001712881

    Shares: 1,625,678.00 · Class: 12.6%

  • NEA 16 GP, LLCReported CIK 0001712882

    Shares: 1,625,678.00 · Class: 12.6%

  • Forest BaskettReported CIK 0001277631

    Shares: 1,625,678.00 · Class: 12.6%

  • Ali BehbahaniReported CIK 0001613867

    Shares: 1,625,678.00 · Class: 12.6%

  • Carmen ChangReported CIK 0001746342

    Shares: 1,625,678.00 · Class: 12.6%

  • Anthony A. Florence, Jr.Reported CIK 0001559827

    Shares: 1,625,678.00 · Class: 12.6%

  • Mohamad H. MakhzoumiReported CIK 0001630226

    Shares: 1,625,678.00 · Class: 12.6%

  • Scott D. SandellReported CIK 0001237289

    Shares: 1,625,678.00 · Class: 12.6%

  • Paul WalkerReported CIK 0001553150

    Shares: 1,625,678.00 · Class: 12.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001072613-25-000647
Form type
SCHEDULE 13D/A
Filer
Marker Therapeutics, Inc.
CIK
CIK 1094038
Filed
Aug 18, 2025
Reporting period
Aug 14, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub